IMMUNOCYTOKINE CONTAINING IL-21R MUTEIN

Provided herein is an immunocytokine comprising (i) an antigen binding protein (ABP) specific to a target protein; (ii) an IL-21 domain; and (iii) an IL-21Rα mutein, wherein the IL-21Rα mutein has a reduced binding affinity to the IL-21 domain compared to a wild-type IL-21Rα. Further provided inc...

Full description

Saved in:
Bibliographic Details
Main Authors KIM Jihye, BAN Hong Seok, SON Ukjin, KWON Hye Mi, LEE Ji-hyung, BAN Jun Su, YANG Seok-woo, LEE Seong Wook, LEE Do Sup, CHO Jea Won, SHON Suh-youn
Format Patent
LanguageEnglish
Spanish
Published 22.04.2024
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein is an immunocytokine comprising (i) an antigen binding protein (ABP) specific to a target protein; (ii) an IL-21 domain; and (iii) an IL-21Rα mutein, wherein the IL-21Rα mutein has a reduced binding affinity to the IL-21 domain compared to a wild-type IL-21Rα. Further provided includes a method of using the immunocytokine to selectively activate an IL-21Rα on a target cell, thereby enhance immune response or treat cancer. En el presente documento, se proporciona una inmunocitocina que comprende (I) una proteína de unión a antígeno (ABP) específica a una proteína objetivo, (II) un dominio IL-21 y (III) una muteína de IL-21Ra, donde la muteína de IL-21Ra tiene una afinidad de unión reducida al dominio IL-21 en comparación a una IL-21Ra de tipo natural. Se proporciona, además, la inclusión de un método para usar la inmunocitocina para activar, selectivamente, una IL-21Ra en una célula efectora para, de este modo, aumentar la respuesta inmunitaria o tratar el cáncer.
Bibliography:Application Number: MX20240003889